Pharma stocks fall as Rep. Cummings launches drug pricing investigation
Chairman of the House Oversight Committee Rep. Elijah Cummings (D-MD) launched an investigation today into the drug pricing practices of 12 pharmaceutical companies. A number of companies named in the investigation saw their stock prices fall, including Amgen (NSDQ:AMGN), AbbVie (NYSE:ABBV), AstraZeneca (NYSE:AZN), Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO). A hearing is reportedly set for Jan. 29 and will include patients affected by rising drug costs. Get the full story at our sister site, Drug Delivery Business News. The post Pharma stocks fall as Rep. Cummings lau...
Source: Mass Device - January 14, 2019 Category: Medical Devices Authors: Sarah Faulkner Tags: Business/Financial News Drug-Device Combinations Featured Pharmaceuticals Wall Street Beat AbbVie Amgen AstraZeneca plc Eli Lilly & Co. Novo Nordisk Sanofi-Aventis Source Type: news

AstraZeneca CMO departs as reorg continues
AstraZeneca's chief medical officer, Sean Bohen is leaving after less than four years at the company, amid the drugmaker's newly announced overhaul. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - January 14, 2019 Category: Pharmaceuticals Source Type: news

AstraZeneca announces plant closings, layoffs
AstraZeneca will be closing two manufacturing sites in Colorado in order to consolidate its biologics manufacturing network in one large-scale drug substance facility. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - January 10, 2019 Category: Pharmaceuticals Source Type: news

After MSKCC, Baselga Heads Oncology R & D at AstraZeneca After MSKCC, Baselga Heads Oncology R & D at AstraZeneca
After stirring up heated controversy over failure to disclose industry relationships while at Memorial Sloan Kettering Cancer Center (MSKCC), Baselga now heads to a giant pharma company.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 8, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Allergan joins biotech swarm in Kendall Square with R & D hub
Yet another of biotech's biggest names is moving to Cambridge. Irish pharmaceutical giant Allergan plc announced plans Monday to open a research facility in Kendall Square during the first quarter of 2019. Former AstraZeneca and Pfizer executive and current Allergan Senior Vice President of Research and External Scientific Innovation Don Frail will oversee th e site, according to a news release. The Botox manufacturer did not disclose where the office would be located or how many employees would… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 8, 2019 Category: Pharmaceuticals Authors: Allison DeAngelis Source Type: news

Top Cancer Doctor, Forced Out Over Ties to Drug Makers, Joins Their Ranks
AstraZeneca has hired Dr. Jos é Baselga, the former chief medical officer at Memorial Sloan Kettering, to lead its cancer research unit. (Source: NYT Health)
Source: NYT Health - January 7, 2019 Category: Consumer Health News Authors: KATIE THOMAS and CHARLES ORNSTEIN Tags: Baselga, Jose AstraZeneca PLC Memorial Sloan-Kettering Cancer Center Drugs (Pharmaceuticals) Conflicts of Interest Source Type: news

AstraZeneca hires former Sloan Kettering specialist to lead oncology R & D unit
AstraZeneca has hired Dr. Jos é Baselga to serve as its head of research and development for oncology. Baselga, 59, was previously chief medical officer at Memorial Sloan Kettering Cancer Center in New York City. He stepped down from that post in September following published reports that he failed at times to disclose certai n financial ties with drug companies in medical journal articles. Baselga also resigned from the Bristol-Myers Squibb Co.'s board of directors that same month. The hiring… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - January 7, 2019 Category: Biotechnology Authors: John George Source Type: news

Flu Shot More Effective Than Nasal Vaccine For Kids, Study Finds
By Jacqueline Howard, CNN (CNN) — When it comes to vaccinating yourself — or your kids — against the flu, there are two options in the United States: a traditional shot or a nasal spray. Yet among children, the nasal spray appeared to have reduced effectiveness against the flu, compared with the shot, in past flu seasons, according to a study published in the journal Pediatrics on Monday. That finding, which involved analyzing data from several previous studies, seems to align with existing research. “We were able to better describe vaccine effectiveness in age groups that the individual s...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - January 7, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News CNN Flu Flu Shot Flu Vaccine Source Type: news

AstraZeneca appoints controversial R & D leader
AstraZeneca has appointed well-known but controversial cancer doctor, Jos é Baselga, to head research and development for oncology, as part of a larger overhaul designed to speed drugs to market (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - January 7, 2019 Category: Pharmaceuticals Source Type: news

AstraZeneca hires controversial head of cancer R&D
Drugmaker ‘doubles down’ on cancer treatments and appoints José Baselga to oversee unit (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - January 7, 2019 Category: Pharmaceuticals Source Type: news

AstraZeneca picks Baselga to lead oncology R & D in growth plan
AstraZeneca said on Monday it had hired Jos é Baselga to head research and development in oncology, an area where the British drugs firm is seeking to grow its business. (Source: Reuters: Health)
Source: Reuters: Health - January 7, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

AstraZeneca appoints Baselga to head R & D for oncology
AstraZeneca Plc has appointed Jos é Baselga to head research and development for oncology as it looks to align the unit with its commercial operations to drive growth. (Source: Reuters: Health)
Source: Reuters: Health - January 7, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

What Can Pharma Expect in 2019?
For those of us that use the Gregorian calendar, this time of year is one for reflection. We look back at the year just gone and forward to the year to come and, armed with a list of best-self resolutions, we step into January full of hope and intention.Like most years, 2018 was a busy one for the pharmaceutical industry – best characterized perhaps not as a year of radical change but as 12 months of under-the-surface action. (But if you disagree,please do let me know).To this editorial team it appears that companies are starting to get to grips with some of the big trends that have swept the industry over the past f...
Source: EyeForPharma - January 7, 2019 Category: Pharmaceuticals Authors: The eyeforpharma Editorial Team Source Type: news

AstraZeneca announces organisational changes
AstraZeneca is today announcing organisational changes to support continued scientific innovation and commercial success in the main therapy areas as the Company enters a new phase in its strategic development. Included in the changes will be the arrival at AstraZeneca of the world-renowned oncology scientist, José Baselga, as well as the creation of: (Source: World Pharma News)
Source: World Pharma News - January 7, 2019 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

Dr. Jan M. Lundberg, Former Head of RandD at AstraZeneca and Eli Lilly has Joined Betagenon's Board of Directors
Dr. Jan M Lundberg brings extensive industrial competence to Betagenon STOCKHOLM, Jan. 3, 2019 -- (Healthcare Sales & Marketing Network) -- "Jan's executive industrial experience as head of R&D at two major pharmaceutical companies, and his involv... Biopharmaceuticals, Personnel Betagenon (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 3, 2019 Category: Pharmaceuticals Source Type: news

Lynparza meets primary endpoint in Phase III SOLO-3 trial for the treatment of relapsed BRCA-mutated advanced ovarian cancer
AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as MSD outside the US and Canada) announced positive results from the randomised, open-label, controlled, Phase III SOLO-3 trial of Lynparza (olaparib) tablets in 266 patients with relapsed ovarian cancer after two or more lines of treatment. (Source: World Pharma News)
Source: World Pharma News - December 27, 2018 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

AstraZeneca's ovarian cancer and anemia treatments meet goals in late-stage studies
British drugmaker AstraZeneca on Thursday said its ovarian cancer and anemia treatments met their goals in three separate late stage trials. (Source: Reuters: Health)
Source: Reuters: Health - December 20, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Lynparza (olaparib) Approved by US FDA for First-Line Maintenance Therapy in BRCA-Mutated Advanced Ovarian Cancer
19 December 2018 -- AstraZeneca and Merck& Co., Inc., (Merck: known as MSD outside the US and Canada) today announced that the US Food and Drug Administration (FDA) has approved Lynparza for use as maintenance treatment of adult patients with... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 19, 2018 Category: Drugs & Pharmacology Source Type: news

Why a kidney disease drug approval in China is just the start for this S.F. company
To win its first-ever drug approval, FibroGen Inc. turned to China, but it's not going to be the San Francisco company's last stop. China's drug regulatory agency Monday approved roxadustat, the first drug of its kind for dialysis patients with anemia caused by chronic kidney disease. San Francisco-based FibroGen's (NASDAQ: FGEN) China subsidiary will manufacture the tablet and partner AstraZeneca plc (NYSE: AZN) will sell the drug starting in the second-half of 2019. But roxadustat's win in China… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - December 18, 2018 Category: American Health Authors: Ron Leuty Source Type: news

Why a kidney disease drug approval in China is just the start for this S.F. company
To win its first-ever drug approval, FibroGen Inc. turned to China, but it's not going to be the San Francisco company's last stop. China's drug regulatory agency Monday approved roxadustat, the first drug of its kind for dialysis patients with anemia caused by chronic kidney disease. San Francisco-based FibroGen's (NASDAQ: FGEN) China subsidiary will manufacture the tablet and partner AstraZeneca plc (NYSE: AZN) will sell the drug starting in the second-half of 2019. But roxadustat's win in China… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - December 18, 2018 Category: Biotechnology Authors: Ron Leuty Source Type: news

AstraZeneca drug gets OK ’d in China before the West
For the first time, China ’s medicines regulator has approved a new drug from a multinational company before regulators in the U.S. or EU. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - December 18, 2018 Category: Pharmaceuticals Source Type: news

China first to approve AstraZeneca, FibroGen anaemia drug
China has become the first country to approve a new anaemia drug from AstraZeneca and FibroGen, well before decisions by regulators in the United States or Europe. (Source: Reuters: Health)
Source: Reuters: Health - December 18, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

AstraZeneca partners on cancer tech center
AstraZeneca announced a new collaboration with Cancer Research UK to launch a center of excellence in genetic screening, cancer modeling and big data processing (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - December 10, 2018 Category: Pharmaceuticals Source Type: news

AstraZeneca and Cancer Research UK launch Functional Genomics Centre to accelerate the discovery of new medicines
AstraZeneca today announced a new collaboration with Cancer Research UK to launch a centre of excellence in genetic screening, cancer modelling and big data processing aimed at accelerating the discovery of new cancer medicines. The Functional Genomics Centre will further develop CRISPR technology to better understand the biology of cancer, (Source: World Pharma News)
Source: World Pharma News - December 10, 2018 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

AstraZeneca's Imfinzi fails to meet main goals in head and neck cancer study
AstraZeneca Plc's immunotherapy Imfinzi did not meet the main goals of a late-stage study testing the drug as a treatment for advanced head and neck cancer, the London-listed drugmaker said on Friday. (Source: Reuters: Health)
Source: Reuters: Health - December 7, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Biocartis partners with AstraZeneca on lung cancer diagnostics
Belgian molecular diagnostics company Biocartis Group said on Thursday it had entered into an agreement with British drugmaker AstraZeneca to obtain faster lung cancer molecular diagnostic biomarker results in Europe. (Source: Reuters: Health)
Source: Reuters: Health - November 29, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Alembic Pharma gets USFDA nod for Alembic Pharma
The approved product is therapeutically equivalent to AstraZeneca Pharmaceuticals' Xylocaine ointment, 5 per cent. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 26, 2018 Category: Pharmaceuticals Source Type: news

AstraZeneca's Pivotal Lung Cancer Trial Fails Main Goal in Late Stage Trial AstraZeneca's Pivotal Lung Cancer Trial Fails Main Goal in Late Stage Trial
AstraZeneca said on Friday its immunotherapy drug Imfinzi did not meet the main goal of improving survival rates for patients with the most advanced form of lung cancer, putting pressure on its shares.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - November 20, 2018 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news

Key AstraZeneca lung cancer treatment misses study goal
AstraZeneca said on Friday its immunotherapy drug Imfinzi did not meet the main goal of improving survival rates for patients with the most advanced form of lung cancer, putting pressure on its shares. (Source: Reuters: Health)
Source: Reuters: Health - November 16, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

AstraZeneca's key lung cancer treatment fails main goal in late-stage trial
AstraZeneca's combination of two immunotherapy drugs did not meet the main goal in a closely watched late-stage study for certain type of stage IV lung cancer, the company said on Friday. (Source: Reuters: Health)
Source: Reuters: Health - November 16, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

AstraZeneca Mystic lung cancer trial fails to deliver results
(Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - November 16, 2018 Category: Pharmaceuticals Source Type: news

How Digital Health Technologies Could Make a Difference
Digital technologies are already changing healthcare. Adherium’s Hailie sensor, for instance, which transforms a traditional inhaler into a smart device, is already reportedly demonstrating reductions in emergency hospital visits. Mark Jones, vice president of R&D for Adherium, will share the story behind Hailie at BIOMEDevice San Jose’s Digital Health Product Spotlight on December 6. He’ll be joined by other digital technology trailblazers Angela McIntyre, executive director of eWear (Stanford Wearable Electronics Initiative); Chalisa Prarasri, CEO & co-founder...
Source: MDDI - November 15, 2018 Category: Medical Devices Authors: Daphne Allen Tags: BIOMEDevice San Jose Digital Health Source Type: news

AstraZeneca sells lung med to Sobi for $1.5 billlion
The company will gain an 8 percent ownership stake in Sobi with the deal's total value reaching $2.3 billion when including deferred and contingency payments (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - November 13, 2018 Category: Pharmaceuticals Source Type: news

Sobi(TM) to Acquire Synagis(R) US Rights From AstraZeneca - Creates a Platform for Global Growth
STOCKHOLM, Nov. 13, 2018 -- (Healthcare Sales & Marketing Network) -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) has entered into agreements to acquire the perpetual rights to Synagis® (palivizumab) in the US from AstraZeneca and to partici... Biopharmaceuticals, Acquisitions Swedish Orphan Biovitrum, Sobi , AstraZeneca, Synagis, palivizumab (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 13, 2018 Category: Pharmaceuticals Source Type: news

AstraZeneca to divest US Synagis rights to Sobi
AstraZeneca has agreed to sell US rights to Synagis (palivizumab) used for the prevention of serious lower respiratory tract infection (LRTI) caused by respiratory syncytial virus (RSV) to Swedish Orphan Biovitrum AB (publ) (Sobi). Sobi will commercialise Synagis in the US and around 130 AstraZeneca employees will transfer to Sobi as part of the transaction. (Source: World Pharma News)
Source: World Pharma News - November 13, 2018 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

Sobi buys rights to AstraZeneca infant drug for $1.5 billion upfront
AstraZeneca has taken another step to refocus on priority drugs by selling U.S. rights to a treatment for infant lung infections to Swedish Orphan Biovitrum for an upfront fee of $1.5 billion. (Source: Reuters: Health)
Source: Reuters: Health - November 13, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

AstraZeneca sells infant drug rights to Sobi for $1.5 billion upfront
AstraZeneca took another step to refocus its portfolio on priority projects on Tuesday by selling U.S. rights to a treatment for a serious infant lung infection to Swedish Orphan Biovitrum for an upfront fee of $1.5 billion. (Source: Reuters: Health)
Source: Reuters: Health - November 13, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

AstraZeneca's diabetes drug curbs heart failure, kidney risks
The biggest clinical trial so far to assess a new class of diabetes pills shows that AstraZeneca's Farxiga can prevent heart failure and cut the risk of kidney problems in a broad range of patients. (Source: Reuters: Health)
Source: Reuters: Health - November 10, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

AstraZeneca diabetes drug cuts complications
Farxiga reduces heart failure and kidney damage during clinical trials (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - November 10, 2018 Category: Pharmaceuticals Source Type: news

An Impatient Truth
15 years ago, I introduced the concept of patient centricity at our first ‘Patient Summits’ in London and Philadelphia. At the time, the idea was somewhat alien; pharmaceutical executives were more interested in patient compliance, the science of getting patients to take their medicine as instructed, and driving sales through repeat prescriptions.The existing language of the day was aggressive. It was all about ‘capturing’ market share and ‘dominating’ the minds of customers. I’ll never forget being berated by one delegate because a conference talk had deviated from the agenda &nda...
Source: EyeForPharma - November 9, 2018 Category: Pharmaceuticals Authors: Paul Simms Source Type: news

AstraZeneca: back from the abyss
Results may appear unimpressive but there is reason to be cheerful (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - November 8, 2018 Category: Pharmaceuticals Source Type: news

AstraZeneca shares surge as new drugs fuel growth
Drugmaker says its first quarter of product sales growth since 2014 ‘marks important day’ (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - November 8, 2018 Category: Pharmaceuticals Source Type: news

Greenberg Traurig London Team Represents Long-time Client AstraZeneca...
The London office of global law firm Greenberg Traurig LLP represented AstraZeneca AB on its agreement with Grünenthal to divest the European rights to Nexium for an upfront payment of USD700...(PRWeb November 08, 2018)Read the full story at https://www.prweb.com/releases/greenberg_traurig_london_team_represents_long_time_client_astrazeneca_ab_in_two_divestment_agreements/prweb15906696.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - November 8, 2018 Category: Pharmaceuticals Source Type: news

AstraZeneca sells 3 more drugs for $350 million
Covis Pharma will pay AstraZeneca $350 million for rights to Alvesco, Omnaris and Zetonna which are three older drugs for asthma and rhinitis (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - November 6, 2018 Category: Pharmaceuticals Source Type: news

Divestment of rights to Alvesco, Omnaris and Zetonna to Covis Pharma
AstraZeneca has entered into an agreement with Covis Pharma B.V. (Covis Pharma) to sell its rights to the medicines Alvesco (ciclesonide), used for the treatment of persistent asthma, and Omnaris and Zetonna (ciclesonide), used for the treatment of nasal symptoms associated with rhinitis. (Source: World Pharma News)
Source: World Pharma News - November 6, 2018 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

AstraZeneca sells trio of respiratory drugs for $350m
(Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - November 6, 2018 Category: Pharmaceuticals Source Type: news

AstraZeneca sells drug rights for $815 million
The company will divest rights to Nexium in Europe and the global rights to Vimovo to Gr ünenthal (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - October 30, 2018 Category: Pharmaceuticals Source Type: news

Agreement with Gr ünenthal for rights to Nexium in Europe and Vimovo worldwide (ex-US)
AstraZeneca has agreed to divest the prescription medicine rights to Nexium (esomeprazole) in Europe, as well as the global rights (excluding the US and Japan) to Vimovo (naproxen/esomeprazole) to Grünenthal. The medicines are outside AstraZeneca's three main therapy areas of Oncology, Cardiovascular, Renal & Metabolism and Respiratory. (Source: World Pharma News)
Source: World Pharma News - October 30, 2018 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

AstraZeneca strengthens and expands oncology development and commercialisation collaboration with Innate Pharma
AstraZeneca, and its global biologics research and development arm MedImmune, announced a new multi-term agreement with Innate Pharma (Innate), building on an existing collaboration, aimed at accelerating each company's oncology portfolio and bringing new medicines to patients more quickly. (Source: World Pharma News)
Source: World Pharma News - October 24, 2018 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

AstraZeneca expands cancer immunotherapy with Innate deal
The drugmaker is buying a 9.8 percent stake in biotech company Innate Pharma, which is run by former AstraZeneca executive Mondher Mahjoubi (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - October 23, 2018 Category: Pharmaceuticals Source Type: news